Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Accruing older patients in clinical trials

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.11.19
Views: 119

Dr Noam VanderWalde - University of Tennessee West Cancer Center, Memphis, USA

Dr Noam VanderWalde speaks to ecancer at the SIOG 2019 meeting in Geneva about the need for accruing older patients in clinical trials.

He explains that despite the fact that the majority of patients in the clinic are older adults, they are massively underrepresented in clinical trials.

Dr VanderWalde reports, through a study carried out with the Alliance for Clinical Trials in Oncology, that one interesting finding was that as the modalities in trials increase, the more difficult it is to accrue older adults.

This service has been kindly supported by unrestricted grants from Janssen Oncology and Sanofi Genzyme.

Related videos

follow us

SIOG metastatic renal cell carcinoma

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation